Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Immunology
Published in: BMC Immunology 1/2015

Open Access 01-12-2015 | Research article

RETRACTED ARTICLE: Oral supplementation of diabetic mice with propolis restores the proliferation capacity and chemotaxis of B and T lymphocytes towards CCL21 and CXCL12 by modulating the lipid profile, the pro-inflammatory cytokine levels and oxidative stress

Authors: Ahmad A. Al Ghamdi, Gamal Badr, Wael N. Hozzein, Ahmed Allam, Noori S. Al-Waili, Mohammed A. Al-Wadaan, Olivier Garraud

Published in: BMC Immunology | Issue 1/2015

Login to get access

Abstract

Background

Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the selective destruction of pancreatic β cells, followed by hyperglycemia, oxidative stress and the subsequent extensive impairment of immune cell functions, a phenomenon responsible for the development of chronic diabetic complications. Propolis, a natural bee product that is extensively used in foods and beverages, significantly benefits human health. Specifically, propolis exerts antioxidant, anti-inflammatory and analgesic effects that may improve diabetic complications. To further elucidate the potential benefits of propolis, the present study investigated the effect of dietary supplementation with propolis on the plasma cytokine profiles, free radical levels, lipid profile and lymphocyte proliferation and chemotaxis in a streptozotocin (STZ)-induced type I diabetic mouse model.

Methods

Thirty male mice were equally distributed into 3 experimental groups: group 1, non-diabetic control mice; group 2, diabetic mice; and group 3, diabetic mice supplemented daily with an ethanol-soluble derivative of propolis (100 mg/kg body weight) for 1 month.

Results

First, the induction of diabetes in mice was associated with hyperglycemia and significant decreases in the insulin level and the lymphocyte count. In this context, diabetic mice exhibited severe diabetic complications, as demonstrated by a significant decrease in the levels of IL-2, IL-4 and IL-7, prolonged elevation of the levels of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and reactive oxygen species (ROS) and altered lipid profiles compared with control non-diabetic mice. Moreover, antigen stimulation of B and T lymphocytes markedly reduced the proliferative capacity and chemotaxis of these cells towards CCL21 and CXCL12 in diabetic mice compared with control mice. Interestingly, compared with diabetes induction alone, treatment of diabetic mice with propolis significantly restored the plasma cytokine and ROS levels and the lipid profile to nearly normal levels. Most importantly, compared with untreated diabetic mice, diabetic mice treated with propolis exhibited significantly enhanced lymphocyte proliferation and chemotaxis towards CCL21 and CXCL12.

Conclusion

Our findings reveal the potential immuno-modulatory effects of propolis, which acts as a natural antioxidant to enhance the function of immune cells during diabetes.
Literature
1.
Castano L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol. 1990;8:647–79.PubMedCrossRef
2.
American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28 suppl 1:S37–42.CrossRef
3.
Le Devehat C, Khodabandehlou T, Vimeux M. Impaired hemorheological properties in diabetic patients with lower limb arterial ischaemia. Clin Hemorheol Microcirc. 2001;25:43–8.PubMed
4.
Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent disease. Arterioscler Thromb. 1992;12:1496–502.PubMedCrossRef
5.
Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, et al. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes. 2008;57:2445–52.PubMedPubMedCentralCrossRef
6.
Kröger J, Zietemann V, Enzenbach C, Weikert C, Jansen EH, Döring F, et al. Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancr and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr. 2011;93:127–42.PubMedCrossRef
7.
Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004;279:42351–4.PubMedCrossRef
8.
Noberaseo G, Odetti P, Boeri D, Maiello M, Adezati L. Malandialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycated hemoglobin. Biomed Pahrmacother. 1991;45:193–6.CrossRef
9.
Gallou G, Ruelland A, Legras B, Mangendre D, Allannic H, Cloarr L. Plasma malondialdehyde in type 1 and 2 diabetic patients. Clin Chim Acta. 1993;214:227–34.PubMedCrossRef
10.
Tsiotra PC, Tsigos C, Raptis SA. TNF alpha and leptin inhibit basal and glucosestimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int J Obes Relat Metab Disord. 2001;25:1018–26.PubMedCrossRef
11.
Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241–8.PubMedCrossRef
12.
Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetes. 2003;52:812–7.PubMedCrossRef
13.
Golbidi S, Badran M, Laher I. Antioxidant and anti-inflammatory effects of exercise in diabetic patients. Exp Diabetes Res. 2012;2012:941868.PubMedCrossRef
14.
Francescato MP, Stel G, Geat M, Cauci S. Oxidative stress in patients with type 1 diabetes mellitus: is it affected by a single bout of prolonged exercise? PLoS One. 2014;9(6):e99062.PubMedPubMedCentralCrossRef
15.
Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci. 2006;1084:89–117.PubMedCrossRef
16.
Foss NT, Foss-Freitas MC, Ferreira MA, Cardili RN, Barbosa CM, Foss MC. Impaired cytokine production by peripheral blood mononuclear cells in type 1 diabetic patients. Diabetes Metab. 2007;33(6):439–43.PubMedCrossRef
17.
Smitherman KO, Peacock JE. Infectious emergencies in patients with diabetes mellitus. Med Clin North Am. 1995;79:53–77.PubMedCrossRef
18.
Mikulkova Z, Praksova P, Stourac P, Bednarik J, Strajtova L, Pacasova R, et al. Numerical defects in CD8 + CD28- T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol. 2010;262:75–9.PubMedCrossRef
19.
Zeidler A, Shargill NS, Chan TM. Peripheral insulin insensitivity in the hyperglycemic athymic nude mouse: similarity to noninsulin-dependent diabetes mellitus. Proc Soc Exp Biol Med. 1991;196:457–60.PubMedCrossRef
20.
Toldi G, Vásárhelyi B, Kaposi A, Mészáros G, Pánczél P, Hosszufalusi N, et al. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels. Immunol Lett. 2010;133:35–41.PubMedCrossRef
21.
Bradshaw EM, Raddassi K, Elyaman W, Orban T, Gottlieb PA, Kent SC, et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol. 2009;183:4432–9.PubMedCrossRef
22.
Ibrahim HM, El-Elaimy IA, Saad Eldien HM, Badr Mohamed B, Rabah DM, Gamal B. Blocking Type I Interferon Signaling Rescues Lymphocytes from Oxidative Stress, Exhaustion, and Apoptosis in a Streptozotocin-Induced Mouse Model of Type I Diabetes. Oxid Med Cell Longev. 2013;2013:148725.PubMedPubMedCentralCrossRef
23.
Von Andrian U, Mackay C. T-cell function and migration: two sides of the same coin. N Engl J Med. 2000;343:1020–34.CrossRef
24.
Garraud O, Borhis G, Badr G, Degrelle S, Pozzetto B, Cognasse F, et al. Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. BMC Immunol. 2012;13:63.PubMedPubMedCentralCrossRef
25.
Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003;112:453–65.PubMedCrossRef
26.
Chan GC, Cheung KW, Sze DM. The immunomodulatory and anticancer properties of propolis. Clin Rev Allergy Immunol. 2013;44:262–73.PubMedCrossRef
27.
28.
AL-Waili N, Al-Ghamdi A, Ansari JM, Al-Attal Y, Salom K. Synergistic Effects of Honey and Propolis toward Drug Multi-Resistant Staphylococcus Aureus, Escherichia Coli and Candida Albicans Isolates in Single and Polymicrobial Cultures. Int J Med Sci. 2012;9:793–800.PubMedPubMedCentralCrossRef
29.
Gekker G, Hu S, Spivak M, Lokensgard JR, Peterson PK. Anti-HIV-1 activity of propolis in CD4(+) lymphocyte and microglial cell cultures. J Ethnopharmacol. 2005;102:158–63.PubMedCrossRef
30.
Orsi RO, Sforcin JM, Funari SRC, Fernandes JA, Bankova V. Synergistic effect of propolis and antibiotics on the Salmonella Typhi. Braz J Microbiol. 2006;37:108–12.CrossRef
31.
Jerza G, Elnakady YA, Brauna A, Jackela K, Sassec F, Al Ghamdi AA, et al. Preparative mass-spectrometry profiling of bioactive metabolites in Saudi-Arabian propolis fractionated by high-speed counter current chromatography and off-line atmospheric pressure chemical ionization mass-spectrometry injection. J Chromatogr A. 2014;13(47):17–29.CrossRef
32.
Dolci P, Ozino OI. Study of the in vitro sensitivity to honey bee propolis of Staphylococcus aureus strains characterized by different sensitivity to antibiotics. Ann Microbiol. 2003;53:233–43.
33.
Mori R, Kondo T, Ohshima T, Ishida Y, Mukaida N. Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration. FASEB J. 2002;16:963–74.PubMedCrossRef
34.
Badr G, Lefevre EA, Mohany M. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS One. 2011;6:e23741.PubMedPubMedCentralCrossRef
35.
Badr G, Mohany M, Abou-Tarboush F. Thymoquinone decreases F-actin polymerization and proliferation of human multiple myeloma cells through suppression of STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis. 2011;10(1):236.PubMedPubMedCentralCrossRef
36.
Badr G, Alwasel S, Ebaid H, Mohany M, Alhazza I. Perinatal Supplementation With Thymoquinone Improves Diabetic Complications and T Cell Immune Responses in Rat Offspring. Cell Immunol. 2011;267(2):133–40.PubMedCrossRef
37.
Badr G, Al-Sadoon MK, El-Toni AM, Daghestani M. Walterinnasia aegyptia venom combined with silica nanoparticles enhances the functions of normal lymphocytes through PI3K/AKT, NFκB and ERK signalling. Lipids Health Dis. 2012;11(1):27.PubMedPubMedCentralCrossRef
38.
Badr G, Garraud O, Daghestani M, Al-Khalifa M, Richard Y: Human breast carcinoma cells are induced to apoptosis by samsum ant venom through an IGF-1-dependant pathway, PI3K/AKT and ERK signaling. Cell Immunol. 2012;273(1):10–6.PubMedCrossRef
39.
Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453:314–21.PubMedCrossRef
40.
Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16:585–601.PubMedCrossRef
41.
Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83:835–70.PubMedCrossRef
42.
43.
Dinh T, Tecilazich F, Kafanas A, Doupis J, Gnardellis C, Leal E, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012;61:2937–47.PubMedPubMedCentralCrossRef
44.
Park JE, Barbul A. Understanding the role of immune regulation in wound healing. Am J Surg. 2004;187:11S–6S.PubMedCrossRef
45.
Zamami Y, Takatori S, Koyama T, Goda M, Iwatani Y, Doi S, et al. Effect of propolis on insulin resistance in fructose-drinking rats. Yakugaku Zasshi. 2007;127:2065–73.PubMedCrossRef
46.
Fuliang HU, Hepburn HR, Xuan H, Chen M, Daya S, Radloff SE. Effects of propolis on blood glucose, blood lipid and free radicals in rats with diabetes mellitus. Pharmacol Res. 2005;51:147–52.PubMedCrossRef
47.
Hu F, Zhu W, Chen M, Shou Q, Li Y. Biological activities of Chinese propolis and Brazilian propolis on streptozotocin induced type 1 diabetes mellitus in rats. Evidence-Based Complementary and Alternative Medicine. 2011;2011:468529.PubMedPubMedCentral
48.
Jasprica I, Mornar A, Debeljak Z, Smolcić-Bubalo A, Medić-Sarić M, Mayer L, et al. In vivo study of propolis supplementation effects on antioxidative status and red blood cells. J Ethnopharmacol. 2007;110(3):548–54.
49.
Kanbur M, Eraslan G, Silici S. Antioxidant effect of propolis against exposure to propetamphos in rats. Ecotoxicol Environ Saf. 2009;72(3):909–15.PubMedCrossRef
50.
Eraslan G, Kanbur M, Silici S, Altinordulu S, Karabacak M. Effects of cypermethrin on some biochemical changes in rats: the protective role of propolis. Exp Anim. 2008;57(5):453–60.PubMedCrossRef
51.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.PubMedCrossRef
52.
Badr G. Supplementation with undenatured whey protein during diabetes mellitus improves the healing and closure of diabetic wounds through the rescue of functional, long-lived wound macrophages. Cell Physiol Biochem. 2012;29:571–82.PubMedCrossRef
53.
Wolf G. New insights into the pathophysiology of diabetic nephrophathy: from haemodynamics to molecular pathology. Eur J Clin Invest. 2004;34(12):785–96.PubMedCrossRef
54.
Franzini L, Do A ’, Zavaroni I. Dietary antioxidants and glucose metabolism. Curr Opin Clin Nutr Metab Care. 2008;11(4):471–6.PubMedCrossRef
55.
Varvarovska J, Racek J, Stetina R, Sýkora J, Pomahacová R, Rusavý Z, et al. Aspects of oxidative stress in children with type 1 diabetes mellitus. Biomed Pharmacother. 2004;58(10):539–45.PubMedCrossRef
56.
Bufalo MC, Bordon-Graciani AP, Conti BJ, de Assis GM, Sforcin JM. The immunomodulatory effect of propolis on receptors expression, cytokine production and fungicidal activity of human monocytes. J Pharm Pharmacol. 2014;66:1497–504.PubMedCrossRef
57.
Agren MS, Schnabel R, Christensen LH, Mirastschijski U. Tumor necrosis factor-alpha-accelerated degradation of type i collagen in human skin is associated with elevated matrix metalloproteinase (mmp)-1 and mmp-3 ex vivo. Eur J Cell Biol. 2015;94:12–21.PubMedPubMedCentralCrossRef
58.
Jung WK, Lee DY, Choi YH, Yea SS, Choi I, Park SG, et al. Caffeic acid phenethyl ester attenuates allergic airway inflammation and hyperresponsiveness in murine model of ovalbumin-induced asthma. Life Sci. 2008;82(13–14):797–805.PubMedCrossRef
59.
Jameson SC. T cell homeostasis: keeping useful T cells alive and live T cells useful. Semin Immunol. 2005;3:231–7.CrossRef
60.
Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol. 2000;5:426–32.CrossRef
61.
Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med. 2002;195(12):1523–32.PubMedPubMedCentralCrossRef
62.
Kikuchi K, Kasai H, Watanabe A, Lai AY, Kondo M. IL-7 specifies B cell fate at the CLP to pre-proB transition stage by maintaining EBF expression. J Immunol. 2008;181(1):383–92.PubMedCrossRef
63.
Colle JH, Moreau JL, Fontanet A, Lambotte O, Joussemet M, Jacod S, et al. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients--effects of antiretroviral therapy. Acquir Immune Defic Syndr. 2006;42(3):277–85.CrossRef
64.
Koesters SA, Alimonti JB, Wachihi C, Matu L, Anzala O, Kimani J, et al. IL-7Ralpha expression on CD4+ T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation. Eur J Immunol. 2006;36(2):336–44.PubMedCrossRef
65.
Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med. 1999;189:451–60.PubMedPubMedCentralCrossRef
66.
Segal MS, Shah R, Afzal A, Perrault CM, Chang K, Schuler A, et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes. 2006;55:102–9.PubMedCrossRef
67.
Aboumrad E, Madec AM, Thivolet C. The CXCR4/CXCL12 (SDF-1) signaling pathway protects non-obese diabetic mouse from autoimmune diabetes. Clin Exp Immunol. 2007;148:432–9.PubMedPubMedCentralCrossRef
68.
Blades MC, Manzo A, Ingegnoli F, Taylor PR, Panayi GS, Irjala H, et al. Stromal cell-derived factor 1 (CXCL12) induces human cell migration into human lymph nodes transplanted into SCID mice. J Immunol. 2002;168:4308.PubMedCrossRef
69.
Badr G, Mohany M, Badr BM, Mahmoud MH, Rabah DM, Garraud O: Treatment of diabetic mice with undenatured whey protein enhances healing of diabetic wounds through the reduction of pro-inflammatory stimuli and modulation of the expression of MIP-1α, MIP-2, CX3CL1 and TGF-β. BMC Immunol. 2012;13:32.PubMedPubMedCentralCrossRef
70.
Mori S, Nakano H, Aritomi K, Wang CR, Gunn MD, Kakiuchi T. Mice lacking expression of the chemokines CCL21-ser and CCL19 (plt mice) demonstrate delayed but enhanced T cell immune responses. J Exp Med. 2001;193(2):207–18.PubMedPubMedCentralCrossRef
71.
Palmer MJ, Mahajan VS, Trajman LC, Irvine DJ, Lauffenburger DA, Chen J. Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol. 2008;5(2):79–89.PubMedPubMedCentralCrossRef
72.
73.
Orsatti CL, Missima F, Pagliarone AC, Bachiega TF, Bufalo MC, Araujo Jr JP, et al. Propolis immunomodulatory action in vivo on Toll-like receptors 2 and 4 expression and on pro-inflammatory cytokines production in mice. Phytother Res. 2010;24:1141–6.PubMedCrossRef
Metadata
Title
RETRACTED ARTICLE: Oral supplementation of diabetic mice with propolis restores the proliferation capacity and chemotaxis of B and T lymphocytes towards CCL21 and CXCL12 by modulating the lipid profile, the pro-inflammatory cytokine levels and oxidative stress
Authors
Ahmad A. Al Ghamdi
Gamal Badr
Wael N. Hozzein
Ahmed Allam
Noori S. Al-Waili
Mohammed A. Al-Wadaan
Olivier Garraud
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2015
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-015-0117-9

Other articles of this Issue 1/2015

BMC Immunology 1/2015 Go to the issue

Research article

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment

Research article

Increased levels of interleukin 31 (IL-31) in osteoporosis

Research article

Immunosenescence of the CD8+ T cell compartment is associated with HIV-infection, but only weakly reflects age-related processes of adipose tissue, metabolism, and muscle in antiretroviral therapy-treated HIV-infected patients and controls

Research article

CD4+CD25High Treg cells in HIV/HTLV Co-infected patients with neuropathy: high expression of Alpha4 integrin and lower expression of Foxp3 transcription factor

Editorial

Still puzzling questions in immunology (infection and immunity)

Research article

Evaluation of immunomodulatory activities of methanolic extract of khat (Catha edulis, Forsk) and cathinone in Swiss albino mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits